Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | IDE | P14735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11108465 | 0.87 | APAF1 (0.38) | SLC6A2SLC6A4SLC6A3SYKAURKB | |
| SCHEMBL5477523 | 0.86 | SYK (0.30) | SYKAURKB | |
| SCHEMBL3827538 | 0.84 | — | — | |
| SCHEMBL1526113 | 0.84 | — | — | |
| SCHEMBL3833143 | 0.84 | — | — | |
| SCHEMBL1414945 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL6401354 | 0.82 | GNAO1 (0.37) | SLC6A2SLC6A4SLC6A3APAF1IDE | |
| SCHEMBL24127552 | 0.82 | — | — | |
| SCHEMBL1393851 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL21354130 | 0.82 | KAT7 (0.33) | SLC6A2SLC6A4SLC6A3SYKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5734056-A | Process for the preparation of certain 9-substituted camptothecins | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-31 | — | — | US | claimed |
| EP-2148882-B1 | PROCESS FOR MAKING TOPOTECAN | SCINOPHARM TAIWAN LDT (TW) | 2012-06-20 | — | — | EP | disclosed |
| US-7977483-B2 | Process for making topotecan | SCINOPHARM TAIWAN, LTD. (TW) | 2011-07-12 | — | — | US | disclosed |
| EP-2148882-A1 | PROCESS FOR MAKING TOPOTECAN | Scinopharm Taiwan, Ldt. (TW) | 2010-02-03 | — | — | EP | disclosed |
| US-20090221826-A1 | Process for making topotecan | SCINOPHARM TAIWAN, LTD. (TW) | 2009-09-03 | — | — | US | disclosed |
| WO-2008127606-A1 | PROCESS FOR MAKING TOPOTECAN | SCINOPHARM TAIWAN, LDT. (TW) | 2008-10-23 | — | — | WO | disclosed |
| EP-0547165-B1 | Process for the Preparation of Water-Soluble Camptothecin Analogues, as well as the compounds 10-Hydroxy-11-C(1-6)-alkoxycamptothecin | SMITHKLINE BEECHAM CORP (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5734056-A | Process for the preparation of certain 9-substituted camptothecins | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0547165-A4 | — | — | 1994-03-30 | — | — | EP | disclosed |
| EP-0547165-A1 | WATER SOLUBLE CAMPTOTHECIN ANALOGUES, PROCESSES AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992005785-A1 | WATER SOLUBLE CAMPTOTHECIN ANALOGUES, PROCESSES AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221826-A1 | Process for making topotecan | TOP2A, TOP1, TOP2B | SLC6A2 1178/4885SLC6A4 1021/4885SLC6A3 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.